Harbour BioMed, a global biopharmaceutical company focused on manufacturing new antibody treatments for immune as well as cancer diseases, has formed a long-term partnership with Yantai Lannacheng Biotechnology Co., Ltd. Together, they will operate on developing next-generation radionuclide drug conjugates (RDCs) to treat cancer more effectively.
RDCs are an advanced type of therapy that uses radioactive substances combined with medicine to directly target cancer cells. This method is more precise than traditional radiotherapy because it specifically targets tumors, reducing harm to healthy tissues. Unlike regular antibody-drug conjugates (ADCs), RDCs can also kill nearby cancer cells, even if those cells don’t have the target protein, making them helpful for tough-to-treat tumors that might resist other therapies.
Harbour BioMed brings advanced technology as well as expertise in antibody development to the collaboration. Their Harbour Mice® platform allows them to create fully human antibodies that are more effective and cause fewer side effects. The company's special heavy chain-only antibodies are smaller than conventional antibodies, making them better for targeting cancer cells directly.
Lannacheng, founded in 2021, is a biotechnology company focused on developing radiopharmaceuticals for cancer. Their research platforms aid improve the design and targeting of radiopharmaceuticals, which enhances the effectiveness of treatments. With strong support from their parent company, Dongcheng Biochem, Lannacheng has the resources to rapidly advance their cancer treatment pipeline.
Together, the two companies will integrate their strengths to make more effective as well as targeted treatments for cancer patients, improving both the diagnosis and treatment process.
As per Coherent Market Insights, the Pharmaceutical Market will grow at a 8.1% compound annual growth rate (CAGR) from 2025 to 2032, from USD 1.81 Tn in 2025 to around USD 3.12 Tn by 2032. This major growth trajectory is driven by the rising healthcare demands, advancements in drug development, and increasing investments in biopharmaceutical research worldwide, positioning the market for robust expansion over the forecast period.
Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented: "We are very pleased to establish a long-term strategic collaboration with Lannacheng to jointly advance the development of next-generation RDCs. Harbour BioMed is committed to providing efficient and highly differentiated antibody solutions for innovative therapies through our globally leading Harbour Mice® fully human antibody platform. This collaboration will deeply integrate Harbour BioMed's expertise in antibody discovery with Lannacheng's strengths in radiopharmaceutical R&D as well as commercialization, accelerating the development of more precise, effective and safe cancer therapies and bringing new hope to patients worldwide."
Source:
News: Harbour BioMed
